evorpacept + pembrolizumab + chemotherapy

This is an investigational **combination therapy** consisting of **evorpacept (ALX148)**, **pembrolizumab**, and **chemotherapy** (typically 5-fluorouracil plus platinum, either carboplatin or cisplatin), studied in advanced solid tumors. - **Evorpacept (ALX148)** is a high-affinity CD47 blocker, functioning as an anti-CD47 SIRPα fusion protein that blocks the "don't eat me" signal used by cancers to evade phagocytosis. - **Pembrolizumab** is a monoclonal antibody acting as a programmed cell death protein 1 (PD-1) inhibitor, enhancing the immune response against cancer cells by releasing the brakes on T cells. - **Chemotherapy** in this setting most often consists of 5-fluorouracil plus either carboplatin or cisplatin, which exert cytotoxic effects and contribute to immunogenic cell death. Together, this combination targets both innate and adaptive immune evasion pathways and has been evaluated in phase 2 studies for efficacy in head and neck squamous cell carcinoma (HNSCC) and other advanced cancers[1][4][7].